CureVac strikes COVID-19 vaccine alliance with Bayer

By Ludwig Burger FRANKFURT (Reuters) - CureVac has signed up Bayer as a partner for its experimental COVID-19 vaccine, keeping a project that is starting late-stage clinical trials in German hands. The move underscores Germany's push for a home-grown vaccine after local rival BioNTech partnered with U.S

Reuters January 08, 2021 00:06:57 IST
CureVac strikes COVID-19 vaccine alliance with Bayer

COVID-19 vaccine alliance with Bayer" src="https://images.firstpost.com/wp-content/uploads/reuters/01-2021/08/2021-01-07T081805Z_1_LYNXMPEH060IT_RTROPTP_2_HEALTH-CORONAVIRUS-CUREVAC-BAYER.jpg" alt="CureVac strikes COVID19 vaccine alliance with Bayer" width="300" height="225" />

By Ludwig Burger

FRANKFURT (Reuters) - CureVac has signed up Bayer as a partner for its experimental COVID-19 vaccine, keeping a project that is starting late-stage clinical trials in German hands.

The move underscores Germany's push for a home-grown vaccine after local rival BioNTech partnered with U.S. drugmaker Pfizer on its COVID-19 inoculation, which is already being rolled out.

"Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance as well as support in selected countries," the companies said.

A spokeswoman for Bayer said the drugmaker would for now play a supporting role in production and would decide during the first quarter whether to manufacture the vaccine for CureVac.

CureVac's shares had surged 14% by 1251 GMT, as traders said the deal gave added assurance on the viability of the biotech firm's technology.

Financial terms were not disclosed.

CureVac last month started a late-stage clinical trial of its COVID-19 vaccine candidate, banking on the same technology that has allowed rivals BioNTech and Moderna to lead the development race.

Nasdaq-listed CureVac, which is backed by investors Dietmar Hopp, the Gates Foundation and GlaxoSmithKline as well as the German government, has said it aims to produce up to 300 million doses of the vaccine in 2021 and up to 600 million in 2022.

Ahead of regulatory approval, the European Union has secured up to 405 million doses of the immunisation, among a slew of supply deals it has agreed with vaccine developers.

Under the deal with Bayer, CureVac will be in charge of obtaining regulatory approval for its vaccine in the EU, while Bayer has options to take that role in other, unspecified markets outside of Europe.

Bayer's pharma unit, which is trying to build a new cell and gene therapy business, has expertise in cancer, haemophilia, multiple sclerosis, cardiovascular diseases and women's health, but not in vaccines.

The group's stock has been battered by billions of euros in writedowns at its agriculture division, litigation woes and a bleaker profit outlook, in large part related to its $63 billion takeover of seed maker Monsanto.

In March last year CureVac was at the centre of a row over alleged attempts by U.S. President Donald Trump to gain access to the vaccine. The company denied at the time having received any U.S. offers for it or its assets.

CureVac has said it would launch in the United States only after the pandemic has been controlled, as the government there had already secured sufficient vaccine quantities from rivals.

(Reporting by Ludwig Burger in Frankfurt and Kirsti Knolle in Berlin; Additional reporting by Hakan Ersen in Frankfurt; Editing by Thomas Seythal, Mark Potter and Jan Harvey)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Target holiday sales jump 17% as shoppers splurge online
Business

Target holiday sales jump 17% as shoppers splurge online

By Uday Sampath Kumar (Reuters) - Target Corp reported a 17.2% rise in comparable sales for the holiday season on Wednesday as its online sales more than doubled, thanks to faster deliveries and higher demand for home goods, electronics and beauty products.

S&P 500, Nasdaq tick higher on Intel boost
Business

S&P 500, Nasdaq tick higher on Intel boost

By Medha Singh and Devik Jain (Reuters) - The S&P 500 and the Nasdaq rose in choppy trading on Wednesday as Intel shares jumped thanks to a change in management while broader sentiment was muted after a recent run to record highs. Intel said it would replace Chief Executive Officer Bob Swan with VMware Inc CEO Pat Gelsinger next month

Bolivia signs contract with India's Serum Institute for 5 million AstraZeneca vaccine doses
Business

Bolivia signs contract with India's Serum Institute for 5 million AstraZeneca vaccine doses

By Danny Ramos LA PAZ (Reuters) - The Bolivian government said on Wednesday it had signed a contract with India's Serum Institute for the supply of 5 million doses of AstraZeneca's COVID-19 vaccine. President Luis Arce said that combined with a recent deal to buy 5.2 million Sputnik V vaccine doses from Russia, Bolivia now expected to be able to inoculate all of its vaccinable population. Both vaccines require two doses to be given, meaning they would be used to inoculate a total of 5.1 million people from Bolivia's 11.51 million-strong population.